Sandoz Says Neulasta Biosimilar Doesn’t Infringe Amgen IP
Law360, San Francisco (December 18, 2017, 8:31 PM EST) — Sandoz Inc. urged a California federal judge Monday to find it hadn’t infringed on Amgen Inc.’s patent related to the biologic Neulasta, which treats chemotherapy side effects, because the recipe for Sandoz’s biosimilar doesn’t involve the …